Our mission is to help breast cancer patients live longer, better lives through earlier detection. We combine new deep learning methods, data science and radiology insights to help doctors find malignancies in mammograms. According to external clinical trial results, Kheiron’s deep learning technology achieves state-of-the-art malignancy detection support in breast cancer screening. European regulatory approval is expected shortly. Combining radiologists' knowledge with modern machine learning enables an entirely new level of diagnostics we can use to detect cancer and improve patient outcomes. According to our externally validated clinical trial results, Kheiron’s solution achieves state-of-the-art performance in breast screening support. Kheiron is proud to be one of the winners of the first UK Government Artificial Intelligence (AI) in Health and Care Awards.
Total Funding: $22.1 M
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2016
Sep 2020
- Kheiron Wins UK Government Award to Help Solve Critical Challenges in UK Breast Screening with Mia
Oct 2019
- UCSF and Kheiron Collaborate in Pioneering Center for Intelligent Imaging
Mar 2019
- Kheiron Launches Mia?, Winner of Aunt Minnie?s ?Best New Radiology Software?
People Partner
London, London
Clinical Implementation Lead - Breast Imaging
London, London
UK Sales Development Lead
London, London
Head of Customer Success
London, London
Partnerships Associate
Los Angeles, California
